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Syncytiotrophoblast derived Extracellular Vesicles (STBEV) from normal pregnancy (NP) 
have previously been shown to interact with circulating monocytes and B cells, and induce pro-
inflammatory cytokine release. Early-onset preeclampsia (EOPE) is associated with an 
exacerbated inflammatory response, yet there is little data regarding late-onset PE (LOPE) and 
immune function. Here, using a macrophage/monocyte cell line THP-1, we investigated the 
inflammatory potential of STBEV, comprising medium/large-STBEV (>200nm) and small-
STBEV (<200nm), isolated from LOPE (n=6) and normal (NP) (n=6) placentae via dual-lobe 
ex-vivo placental perfusion and differential centrifugation. THP-1 cells bound and internalised 
STBEV isolated from NP and LOPE placentae, as revealed by flow cytometry, confocal 
microscopy and ELISA. STBEV-treated THP-1 cells were examined for cytokine gene 
expression by RT-qPCR and the cell culture media examined for secreted 
cytokines/chemokines. As has been previously reported, NP medium/large-STBEV 
significantly upregulated the transcriptional expression of TNF-α, IL-10, IL-6, IL-12, IL-8 and 
TGF-β compared to PE medium/large-STBEV, however there was no significant difference in 
the small STBEV population between the two groups though in general, NP small STBEVs 
slightly upregulated the same cytokines. In contrast, LOPE STBEV (medium and large) did 
not induce pro-inflammatory responses by differentiated THP-1 macrophages. This decreased 
effect of LOPE STBEV was echoed in cytokine/chemokine release. Our results appear to 
suggest that STBEV from LOPE placentae do not have a major immune-modulatory effect on 
macrophages. In contrast, NP STBEV caused THP-1 cells to release pro-inflammatory 
cytokines. Thus, syncytiotrophoblast extracellular vesicles from LOPE dampen immune 
functions of THP-1 macrophages, suggesting an alternative mechanism leading to the pro-
inflammatory environment observed in LOPE. 
 



















Preeclampsia (PE) is a pregnancy-specific syndrome, characterised by new-onset maternal 
hypertension and proteinuria or organ dysfunction, amongst other symptoms. PE is commonly 
divided into two subgroups: early-onset PE (EOPE), occurring ≤ 34-weeks gestation, and late-
onset PE (LOPE), occurring ≥ 34-week gestation.  The pathophysiology of EOPE is widely 
believed to lie with the placenta (1). Immune imbalance (2–4) and cardiovascular dysfunction 
(5,6) are highly significant in EOPE patients.  The cause of the LOPE is more controversial, 
with some suggesting its placental origin (1,7); another school of thought suggested maternal 
stress response as a pathogenic mechanism due to an incompatibility between the metabolic 
demands of the growing fetus close to term and maternal supply (8–10). The immunology of 
pregnancy involves crosstalk between a diverse population of immune and non-immune cells 
such as uterine natural killer cells (uterine NK cells), decidual macrophages, T cells, the 
syncytiotrophoblast, decidual stromal cells and extravillous trophoblast cells through soluble 
factors like cytokines or chemokines and syncytiotrophoblast extracellular membrane vesicles 
(STBEVs). The uterine NK cells produce both pro (type 1 response) such as IL-12, IL-15, IL-
18 and IFN-γ and anti-inflammatory cytokines (type 2 response) such as IL-4 and IL-10(11), 
which interact with the human leukocyte antigen (HLA) antigens on the extravillous 
trophoblasts (EVT) (12). Similarly, T cells, in particular T helper cells, mainly exist in the form 
of Th1 or Th2 phenotype. The Th1 phenotype predominates (5-30 % of T cells)(13) in the first 
trimester produce pro-inflammatory cytokines such as IL-2, TNF-α and IFN-γ (type 1 
response), recruit essential immune cells and help direct implantation, regulate trophoblast 
invasion by altering trophoblast cell adhesion to laminin(14) and elevation plasminogen 
activator inhibitor-1 (15,16) and activate or prepare for the activation of the mechanism of 
labour(17). IFN-γ regulates peri-implantation vascular remodelling(18,19) and extra villous 
trophoblast invasion. Th2 cells release type 2 cytokines such as IL-10, IL-4 and IL-13 and are 
critical in immunosuppressing and reducing the pro-inflammatory responses. Like T helper 
cells, decidual macrophages predominates in two forms, M1 which are involved in the type 1 
pro-inflammatory response and M2 macrophages which are involved in towards anti-
inflammatory type 2 response. Like Th1 and Th2, M1 and M2 are antagonistic in their 
downstream functions and co-regulate each other’s actions but may switch depending on the 
microenvironment between phenotypes. 
There is a failure of this immunotolerance in preeclampsia, resulting in poor placentation. 
However, no clear immunological distinction has been made between EOPE and LOPE. 
Elevation of type 1/pro-inflammatory and reduction of type 2/anti-inflammatory cytokines 
have been detected in the serum and placenta of preeclampsia patients(20). In addition, 
epidemiological studies that have found an association between preeclampsia and primi-
paternity (21,22) and sperm exposure (23) highlight a potential role of immunology in the 
pathogenesis of preeclampsia. Two types of Th1/Th2 predominant preeclampsia have been 
described, a more common Th1 predominant type and a less common Th2 predominant type. 
In the Th2 predominant preeclampsia is caused by the production of allo- or autoantibodies 
(antiphospholipid antibodies), which can inhibit the invasion of trophoblasts in the decidua 
(11). This finding has also been observed in macrophages with a polarisation to M1 
macrophage phenotype observed in preeclampsia (24). In addition, studies have identified an 
increased number and activation of macrophage in preeclampsia(21,22), which may contribute 
to the limited trophoblast invasion and spiral artery remodelling. 
Extracellular vesicles (EV) are membrane-bound complexes extruded from cells and are potent 
signalling modulators of the immune system under both physiological and pathological 
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conditions (25).  In pregnancy, the syncytiotrophoblast (STB) and the maternal immune system 
communicate via the release of soluble factors such as chemokines, cytokines, complement, 
steroid and protein hormones, as well as by factors carried by EV (26). As recommended by 
the MISEV 2018 guidelines (27), STB derived EVs (STBEV) comprise two subgroups 
according to their size: medium/large STBEV ( > 200 nm) and small STBEV ( < 200 nm), (28). 
STBEVs have immunomodulatory roles during pregnancy (26,28,29).  STBEVs, isolated from 
perfused normal placentae (NP), has been shown to bind to B cells and monocytes and enhance 
the release of pro-inflammatory cytokines by peripheral blood mononuclear cells (PBMCs) and 
monocytes (30–33).  Medium/large STBEV isolated from PE placental explants have also been 
shown to further enhance the secretion of pro-inflammatory cytokines and chemokines in 
PBMCs, including IL-1β, when compared to NP medium/large STBEV (34).  Similarly, 
PBMCs, treated with medium/large STBEV derived from trophoblast cells grown under 
hypoxic conditions release higher IL-6 and TNF-α compared to PBMCs cultured alone (35).   
STBEVs have been shown to circulate in increased levels in maternal peripheral plasma (36), 
especially in EOPE (37,38). The different STBEV subtypes (medium/large STBEV and small 
STBEV) and their interaction with macrophages have not been studied.  Previous studies have 
(a) used pooled EVs (which do not distinguish the effects of small STBEVs from medium/large 
STBEVs); (b) used term placentae taken from a caesarean section or vaginal delivery (vaginal 
delivery subjects placenta to labour stresses (39)); or (c) not clearly defined the PE disease state 
(30,31,33).  Considering that research has been mostly focused on EOPE placentae, we decided 
to concentrate our studies on LOPE derived STBEV. 
Our hypothesis was that STBEV derived from LOPE placentae would cause an exacerbated 
inflammatory effect on human THP-1 macrophages compared to STBEV obtained from the 
placenta from normal pregnancy similar to that seen from EOPE.  To investigate this, we 
examined (1) whether THP-1 cells would internalise STBEV derived from NP or LOPE 
perfused placentae, (2) if there was any difference in the uptake of STBEV derived from NP 
and LOPE placentae; and (3) whether STBEV isolated from LOPE placentae would induce an 
altered inflammatory response to THP-1 compared to those derived from NP.  
MATERIALS AND METHODS 
Human Subjects 
The human subjects’ material used in this project was approved by the Central Oxfordshire 
Research Ethics Committee C (REF 07/H0607/74 & 07/H0606/148).  All mothers undergoing 
elective caesarean section without labour were consented for the use of their placentae by 
research midwives.  Mothers suffering from PE were recruited using the corresponding 
diagnostic criteria defined by the International Society for the Study of Hypertension in 
Pregnancy (ISSHP) (40). According to ISSHP, PE is defined as de novo hypertension in the 
second half of pregnancy (>140/90 mm Hg) accompanied with one or more complications: 
new proteinuria (>300mg per 24 hours), or another maternal organ dysfunction.  The clinical 
characteristics of PE patients and controls (NP) are summarised in Table 1. 
Isolation and Characterisation of STBEV 
STBEV were prepared using a modified dual-lobe placental perfusion system with human 
placentae, and differential centrifugation, and characterised , as previously described (41).  
Briefly, a suitable placenta lobe without calcifications or areas of necrosis was identified, 
cannulated and perfused with Medium 199 with L-glutamine and Earle’s salts containing 0.5% 
w/v Bovine serum albumin (BSA; Sigma U.K), 0.8% Dextran 20 and 500 U/L sodium heparin 
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with (foetal) or without (maternal) dextran for 3 hours.  The resultant maternal perfusate was 
initially centrifuged at 2500 x g twice to get rid of red blood cells and cell debris. The 
supernatant was then centrifuged at 10,000 x g for 30 minutes at 4oC, the pellet was 
resuspended in filtered PBS and termed as medium/large STBEVs; the supernatant was further 
centrifuged at 150,000 x g for 2 hours at 40C and the pellet resuspended in filtered PBS and 
classified as small STBEVs. Leukocytes depletion was done with the human CD45 depletion 
kit (EasySepTM). The two fractions were characterised by transmission electron microscopy 
(TEM), standard flow cytometry, nanoparticle tracking analysis (NTA), and western blot, 
which confirmed our fractions were indeed enriched for medium/large and small STBEVs 
respectively.  
Cell culture 
THP-1 cells, originally derived from human acute monocyte leukaemia cell line (ATCC® TIB-
202™), were cultured in RMPI-1640 medium (Gibco) containing 10% v/v fetal calf serum 
(FCS), 2mM L-glutamine, 100U/mL penicillin and 100 µg/mL streptomycin. FCS was 
centrifuged at 150,000 x g for 18 hours using a Beckman L8-80M ultracentrifuge and filtered 
at 0.1 μm under sterile conditions to reduce possible contamination of FCS EVs. THP-1 cells 
were adjusted to 5 x 105 cells per well in a 24-well plate and differentiated into macrophage-
like phenotype using 50 ng/mL of Phorbol 12-Myristate 13-Acetate (PMA; Sigma) in RPMI-
1640 complete medium (including 10% v/v EV-free FCS) for 48 hours at 37ºC under 5% v/v 
CO2.  
THP-1 treatment with STBEV 
NP medium/large STBEV from 6 NP were pooled together based on equal protein 
concentration. This was also true for NP small STBEV, LOPE medium/large STBEV and 
LOPE small STBEV. It has been widely reported that there is a greater shedding/release of 
STBEV in PE, especially in EOPE (36). Furthermore, it is likely that different sized EVs will 
express different protein cargo based on their heterogeneity. Thus, we chose to use the same 
particle number rather than protein concentration. To do this, medium/large STBEV and small 
STBEV were analysed by Nanoparticle Tracking Analysis (NTA); further dilution in serum-
free media was carried out to achieve the same particle number among NP and PE 
medium/large STBEV or small STBEV (1 x 109 particles/mL).  STBEVs were incubated with 
differentiated THP-1 cells for 2 and 6 h for qPCR, and 12 and/or 24 h for multiplex 
cytokine/chemokine array analysis.  THP-1 cells with no STBEV were used as a control for 
each time point.  The supernatant was collected, and dead cells and debris were removed by 
centrifugation at 1,500 x g for 10 minutes at 4C, and stored at -80C.  
Flow cytometry analysis of THP-1 cells treated with Bio-maleimide stained STBEV  
Medium/large STBEV from NP or LOPE placentae were pre-stained with 2 µM of Bio-
maleimide (Molecular Probes) [previously filtered using a 0.2 µm nanosep centrifugal device 
(VWR)] for 30 minutes at room temperature in the dark and washed with PBS by centrifugation 
at 10,000 x g at 4°C for 35 minutes prior to flow cytometry analysis. After treatment of STBEV 
(1 x 109 particles/mL) to THP-1 macrophages (5 x 105 cells/well), cells were lifted with 
Trypsin-EDTA (Sigma) and fixed with 1 mL of 2% v/v paraformaldehyde (PFA).  Finally, the 
pellet was re-suspended in 300 µL of filtered PBS and 5,000 events were recorded per sample 




Confocal microscopy of THP-1 cells treated with PKH26-stained STBEV  
STBEVs from each patient group were pre-stained with PKH26 dye (red; MINI26; Sigma), the 
THP-1 cells’ membrane were labelled with WGA-Alexa 488 (green; Vector Laboratories), and 
the cell nuclei with Hoechst 33342 (blue; Sigma).  THP-1 cells alone were used as a control. 
Cells were viewed under a Zeiss confocal microscope with a Yokogawa spinning disk scanning 
unit and an attached Evolve® 512 Delta EMCCD camera, and images were taken using Zen 
Blue software (Zeiss).  Z-stacks (11 slices) were taken through a 10µm depth, and pictures 
were compressed on maximum intensity using ImageJ software (Fiji).  
PLAP ELISA 
Microtitre well in a 96-well MaxiSorp plate (Nunc) were coated overnight with 100 µL of 10 
µg/mL PLAP antibody (NDOG2).  The wells were washed with PBS-T (PBS + 0.05% Tween 
20) and incubated with 300 µL of blocking buffer (5% w/v BSA in PBS-T) for 3 hours.  For 
ELISA, NP medium/large STBEVs derived from 3 mothers were pooled and serially diluted 
(4,000 ng/mL down to 1 ng/mL) in 1% BSA + PBS-T. Untreated and treated THP-1 cells were 
extensively washed to get rid of uninternalised and unbound STBEVs, after which both groups 
of THP-1 cells were added to the plate and incubated in triplicates. Following an overnight 
incubation, the wells of the plates were thoroughly washed using PBS-T to get rid of unbound 
targets.  1-Step pNPP (p-nitrophenyl phosphate disodium salt) substrate kit (Sigma) was used 
to detect alkaline phosphatase activity.  100 µL of the substrate was added to each well and 
incubated for 1 hour and 30 minutes. 50 µL of 2N sodium hydroxide (NaOH) was added to 
stop the reaction. Absorbance was measured at 405nm using the FluoStar OPTIMA (BMG) 
plate reader. 
Quantitative real-time RT-qPCR for cytokines expression 
RNA was extracted using the RNeasy micro kit (Qiagen) followed by treatment with DNA-
free removal kit (ThermoFisher) to remove any contaminating genomic DNA prior undergoing 
RT-qPCR reaction. The RNA concentration was measured using a NanoDrop ND-1000 
Spectrophotometer (ThermoFisher) at 260 nm absorbance, and RNA purity was assessed using 
the 260:280 nm absorbance ratio.  Samples were diluted with RNase-free water and adjusted 
to 100 ng/μL concentration.  RNA samples were converted into cDNA using a High capacity 
RNA-cDNA conversion kit (Applied Biosystems).   
The nucleotide Basic Local Alignment Search Tool and Primer-BLAST were used to design 
and analyse the specificity of the primer sequences.  Primers sequences are listed in Table 2.   
RT-qPCR reaction contained 3.7 μL of RNase-free water, 5 μL Power SYBR Green Master 
mix (Applied Biosystems), 75 nM of forward and reverse primers and 100 ng template cDNA 
in a final reaction volume of 10 μL, run in a 7900HT fast Real-Time RT-qPCR system (Applied 
Biosystems).  The RT-qPCR reaction initially included 2 minutes of incubation at 50°C, 
followed by 10 minutes incubation at 95°C.  The template was then amplified for 40 cycles 
under the following conditions: 15 seconds incubation at 95°C and 1-minute incubation at 
60°C.  The single housekeeping gene, 18S, was included in each RT-qPCR reaction set to 
normalise the rest of the samples against the expression of human 18S rRNA.  Data were 
acquired using the RQ Manager Version 1.2.1 (Applied Biosystems).  Ct (cycle threshold) 
values for each target gene expression were calculated, and Relative Quantification (RQ) 
values for each cytokine target gene was calculated using the formula: RQ= 2-ΔΔCt.  Assays 
were carried out twice in triplicate.  
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Multiplex cytokine array analysis  
Supernatant samples collected in previous THP1-STBEV treatment experiments were analysed 
using a Milliplex ® MAP Human cytokine/chemokine magnetic bead panel kit (HCYTOMAG-
60K; EMD Millipore).  Briefly, in a 96-well plate, 25 μL of assay buffer was added to each 
well.  This was followed by the addition of 25 μL of standard, control and supernatant samples.  
The 96-well plate was washed with assay buffer, and 25 μL of target antibodies were incubated 
with the beads for 1 hour at room temperature.  25 μL of Streptavidin-Phycoerythrin conjugate 
was then added to each well and incubated for 30 minutes in the dark at room temperature.   
After washing step with the assay buffer, 150 μL of sheath fluid was added to each well, and 
the plate was read using the Luminex Magpix instrument.   
Statistical Analysis 
The data were analysed using GraphPad 9 software. Multiplex cytokine array data were 
analysed with one-way ANOVA and presented as mean ± SEM cytokine concentration. 
Multiple hypothesis testing was corrected for by using statistical hypothesis testing (Tukey). 
For qPCR analysis, one-way ANOVA was done on the ΔCT values with a similar stastical 
method applied as for the multiplex cytokine array data analysis. Graph for the qPCR data was 
presented as mean ± SEM log (2) fold change.   
RESULTS 
Characterisation of small and medium/large STBEVs by Western blot (WB), Nanoparticle 
tracking analysis (NTA), flow cytometry and transmission electron microscopy (TEM) 
Characterisation of enriched STBEV fractions was confirmed using western blotting assays for 
the classical EV markers, tetraspanins (CD81, CD63), an endosomal trafficking protein marker 
(ALIX and TSG101) and a non-EV marker (Cytochrome C) as negative control (Figure 1A). 
Immunoblotting revealed the presence of placenta alkaline phosphatase (PLAP [66 KDa]), 
typical EV markers (CD63, [30–65 KDa], CD81 [20 KDa], and ALIX [ 95 KDa] and TSG101 
[46 KDa]) (Figure), while the cytochrome C [12 KDa], the negative EV marker was not 
detected in the STBEV fractions but was detected in the placenta lysate. TSG101 and ALIX 
were more prominent in the small STBEV fractions than the medium/large STBEV fractions 
and placenta lysate. Flow cytometric analysis shows that most of the particles analysed were 
vesicular ( greater than 240 nm and less than 1µm in size and 92.8 % Biomalemide positive [ 
Figure 1A]) and syncytiotrophoblast derived (87.8 % express PLAP [Figure 1C],  97.8% are 
MHC class I/II negative [ Figure 1E]) with little contamination from platelets and red blood 
cell vesicles ( only 19.4% of the vesicles are platelets and red blood cell-derived [Figures 1C 
and 1D]). We could not study the small STBEVs because they are below the level of detection 
of a standard flow cytometer. Nanoparticle tracking analysis for the size distribution of 
medium/large and small STBEV fractions showed a modal size of 245.8 ± 7.9 nm and size of 
176.3 ± 7.5 nm, respectively (Figure 2 A and D). A close-up view of transmission electron 
microscopy (TEM) revealed the characteristic ‘cup shaped’ morphology and size range of 
extracellular vesicles in both medium/large (Figure 2C) and small (Figure 2F) STBEV 
fractions. Figure 2 B and E are wide-angle view of medium/large and small STBEV fractions, 
respectively, along with their co-isolates. Together, these results confirmed that our fractions 




Medium/large STBEV from NP and LOPE are taken up by differentiated THP-1 cells  
Uptake of NP and LOPE medium/large STBEV by differentiated THP-1 cells was investigated 
by flow cytometry via Bio-maleimide (STBEV membrane marker, FITC) and HLA-ABC 
(THP-1 cell marker; PeCy7) co-expression (n=3, Figure 3).  Our data revealed that treatment 
of THP-1 cells with NP and LOPE medium/large STBEV showed a double positivity 
(FITC+PeCy7+) at 2 hours (NP: 70% ± 5.6, LOPE: 54% ± 8.6; p>0.05) and 6 hours (NP: 75% 
± 4.2, LOPE: 78% ± 6.6; p>0.05), demonstrating uptake of medium/large STBEV by THP-1 
cells (Quadrant Q2-2; Figure 3.A).  Although the uptake of medium/large STBEV in THP-1 
cells revealed a significant difference in the co-expression of Bio-maleimide and HLA-ABC 
compared to untreated cells (2 h: p≤0.01; 6 h: p≤0.001), there was not a significant difference 
in uptake between medium/large STBEV derived from NP and LOPE placentae (p= 0.021; 
Figure 3.C), suggesting a comparable level of phagocytosis.  We could not study the small 
STBEVs because they are below the level of detection of standard flow cytometer.  
Confocal microscopy analysis confirmed internalisation of STBEV from NP and LOPE 
placentae into THP-1 macrophages 
Confocal microscopy was used to assess whether STBEV (technical replicate = 3) were being 
internalised by differentiated THP-1 cells at different time points (2 and 6 hours; Figure 4 and 
5). Medium/large STBEV derived from NP and LOPE medium/large STBEV placentae (Figure 
4), and NP and LOPE small STBEV (Figure 5) appeared to be internalised by THP-1 cells. The 
internalisation of STBEV by THP-1 cells appear to be time-dependent as the image obtained 
after six hours looks more intensely stained than the image obtained after two hours of 
incubation for both LOPE and NP.  
PLAP ELISA confirmed internalisation of STBEV from NP and LOPE patients into THP-1 
macrophages 
To quantitate the STBEV taken up by THP-1 cells, PLAP (a specific marker of STBEV, thus 
not natively expressed in THP-1 cells) was measured using a standard ELISA. We confirmed 
that STBEV were indeed taken up by THP-1 cells (n=3; Figure 6). This quantification included 
the internalised STBEV and those bound to the cell membrane of THP-1.  Medium/large 
STBEV taken up by THP-1 was also time-dependent, although there was no significant 
difference between each group, i.e. NP and LOPE (small STBEV uptake showed a significant 
difference between NP and LOPE at 6-hour time-point (NP < LOPE small STBEV: p<0.001). 
These findings corroborate our confocal microscopy data in regards to small STBEV 
internalisation by THP-1 cells. However, we should take into account that PLAP expression is 
reduced in PE derived STBEV (42); thus, our results might be underestimated.  Hence, we can 
only determine that both medium/large STBEV and small STBEV from NP and LOPE are 
taken up by THP-1 without a significant difference. 
NP medium/large STBEV significantly upregulated mRNA expression of TNF-α, IL-10, IL-6, IL-
12, IL-8 and TGF-β in THP-1 macrophages. 
Quantitative real-time RT-qPCR analysis was used to investigate the gene expression of a 
selected group of cytokines in differentiated THP-1 cells incubated with STBEV derived from 
NP and LOPE placentae (n=3; Figure 7 and 8) for 2 and 6 hours. Analysis was done with the 
ΔΔ CT (43) method, and statistical testing was done on the ΔCT values. 
At 2 hours of incubation, TNF-α mRNA was significantly upregulated by NP medium/large 
STBEV (fold change of 8.735 relative to untreated THP-1 cells hereafter referred to as FC, 
Figure 7A), compared to PE medium/large STBEV (FC of 1.24) while TNF-α mRNA was 
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upregulated by NP small STBEV (FC of 3.72) compared to LOPE small STBEV (FC of 0.37, 
Figure 8A) though this difference was not significant. After 6 hours of incubation, TNF-α was 
upregulated by NP medium/large STBEV (FC of 5.95) in comparison to  LOPE medium/large 
STBEV  (FC of 0.63) [(medium/large STBEV: at 2 hours p< 0.0001, at 6 hours p< 0.0001] 
while no significant difference was found in small STBEV but the NP group appeared to mildly 
increase transcripts level while the LOPE group suppressed transcript levels.  
Similarly, at 2 hours, IL-6 was highly expressed in THP-1 cells incubated with NP 
medium/large STBEV (FC of 7.06, Figure 7F), and its expression increased significantly over 
time (FC of 38.21).  NP medium/large STBEV brought about a greater change in IL-6 
expression compared to LOPE medium/large STBEV at both 2 and 6 hours of incubation (p< 
0.0001). There was no significant difference in the induction of IL-6 in NP compared to LOPE 
small STBEV (Figure 8F).   
Likewise, IL-12 was more expressed at 2 hours in cells treated with NP medium/large  (Figure 
7D)  STBEV compared to LOPE ( NP FC= 3.21 LOPE FC= 0.66, P < 0.01) and at 6 hours ( 
NP FC= 6.39 LOPE FC= 0.77, P < 0.01). There was no significant difference in cells treated 
with small STBEV from both groups. However, unlike NP SMALL STBEV  at 2 hours, which 
caused a modest upregulation in IL-12, the rest seem to have reduced expression compared to 
untreated THP-1 cells [(NP FC (2 hours) = 1.15, LOPE FC (2 hours)= 0.88, NP FC (6 hours) 
= 0.52 LOPE FC (6 hours)= 0.678, Figure 8D)]. 
There was no significant difference in TGF-β expression between small (Figure 8B)  and 
medium/large STBEV (Figure 7B) between NP and LOPE;  both groups did not cause an 
increased expression of TGF- β compared to untreated THP-1 cells. However, at 2 hours of 
incubation, IL-10 mRNA was significantly upregulated by NP medium/large STBEV (FC of 
22.23) compared to LOPE medium/large STBEV (FC of 4.36, p< 0.0001), but at 6 hours, there 
was no significant difference between both groups (Figure 7C). Whilst treatment of THP-1 
cells with small STBEV resulted in an upregulation of the transcript [FC: PE small STBEV (2 
hours)-3.70, NP small STBEV (2 hours)-3.06, PE small STBEV (6 hours)-3.95, NP small 
STBEV (6 hours)-3.69, Figure 4I], this was not significantly different between NP and LOPE. 
Besides, LOPE medium/large STBEV significantly increased expression of IL-8 compared to 
NP at both 2 and 6 hours (p< 0.0001; Figure 7E). There was a slight suppression of IL-8 with 
small STBEV from NP at 2 hours (FC=0.75), which increased at 6 hours (FC=1.63, Figure 8E) 
while LOPE small STBEV failed to induce IL-8 expression. However, there was no significant 
difference between the two groups at both 2 and 6 hours. 
Overall, THP-1 macrophages challenged with medium/large NP STBEV showed upregulation 
of pro-inflammatory cytokines, while though small STBEV did not induce significant 
alterations in the cytokine profile consistent with the higher uptake, they still modestly 
increased the levels of transcripts of pro-inflammatory cytokines.  Surprisingly, LOPE STBEV 
brought about modest changes in the expression of pro-inflammatory cytokines whilst LOPE 
small STBEV induced upregulation of IL-10 transcripts and downregulated the expression of 
other transcripts at 2 hours.  These results appear to suggest that NP-derived medium/large 
STBEV and small STBEV induce pro-inflammatory responses, whereas those derived from 
LOPE placentae (whilst clearly being internalised) do not cause an inflammatory response.  
The finding of upregulated IL-10 by LOPE derived small STBEV appears to suggest an anti-




NP-STBEV cause a significant release of TNF-α, IL-8, IL-6, MIP1-, IP-10, MCP-1, VEGF, 
IL-1β, and GM-CSF from THP-1 cells compared to LOPE STBEV 
Multiplex array analysis was used to investigate the secreted levels of a range of cytokines, 
chemokines, growth factors, and soluble ligands following 12- and 24- hours incubation of 
differentiated THP-1 cells with STBEV derived from NP and PE placentae (Figure 9 and 10).  
THP-1 cells challenged with NP medium/large STBEV appeared to show a predominantly pro-
inflammatory profile, as evident from the significant higher quantities of TNF-α (9A), IL-6 
(9D) IL-1β (10b), GM-CSF (10C) and IL-12p40 (10D), secreted in the supernatant compared 
to very feeble, if any,  secretion by LOPE medium/large STBEV treated THP-1 cells at both 
time points (TNF-α, IL-1β, IL-6, GM-CSF = p<0.0001; IL-12p40 = p<0.001). Similarly, THP-
1 challenged with NP small STBEV in comparison to PE small STBEV revealed the same trend 
as medium/large STBEV. NP medium/large STBEV treated THP-1 cells released around 2-
fold higher levels of anti-inflammatory cytokine IL-10 (9B) compared to LOPE medium/large 
STBEV (p = 0.0026 at 12 hours, <0.0001 at 24 hours) at both time points. There was only a 
significant difference between NP small STBEV treated THP-1 release of IL-10 at 12 hours in 
comparison to LOPE small STBEV (p=0.0204). Although IL-10 transcripts were upregulated 
in LOPE small STBEV, this is not consistent with the protein production by THP-1 after longer 
incubation with LOPE small STBEV. 
Chemokines IL-8 (9C), MIP-1α (9E), MCP-1 (9F) and IP-10 (10E) were also secreted in higher 
quantities in response to NP medium/large STBEV compared to LOPE medium/large STBEV, 
as well as NP small STBEV compared to LOPE small STBEV. Particularly, NP medium/large 
STBEV released about 4 and 2.3 folds more IL-8 in treated THP-1 cells compared to LOPE 
medium/large STBEV (12 hours: p≤ 0.0001, 24 hours: p = 0.0001, Figure 9C) at 12 and 24 
hours respectively. Similarly, IL-8 was secreted 3.3 and 1.7 folds more by THP-1 cells when 
induced with NP small STBEV compared to LOPE small STBEV (12 hours: p≤ 0.0001, 24 
hours: p = 0.0014, Figure 9C).  Both NP medium/large STBEV and NP small STBEV 
stimulated the IL-8 release of over 12,500 pg/mL, whilst LOPE medium/large STBEV and 
LOPE small STBEV also seemed to increase production of IL-8 but at a lower level (12 hours: 
< 5,000 pg/mL, 24 hours: > 5,000 pg/mL).   Thus, NP STBEV challenged THP-1 cells secreted 
more IL-8 than LOPE STBEV.   
In addition, NP medium/large STBEV produces 10.5 folds more MIP-1 α in THP-1 cells 
compared to LOPE medium/large STBEV at 24 hours (p ≤ 0.0001,Figure 9F). NP small 
STBEV also induced 24.8 and 3.1 folds more MIP-1α than LOPE small STBEV (12 hours: p≤ 
0.0001, 24 hours: p≤ 0.05, Figure 9E) at 12 and 24 hours, respectively.  Intriguingly, NP small 
STBEV produced 25 folds more MIP-1α after 12 hours of incubation than NP medium/large 
STBEV (p≤ 0.0001); this effect was then reversed at 24 hours though not significant. Thus, our 
results revealed that MIP-1α was released in greater quantities by THP-1 cells when challenged 
with NP STBEV in comparison to cells challenged with LOPE STBEV.   
Finally, at 12 hours ,VEGF was secreted in higher quantities by THP-1 challenged with NP 
medium/large STBEV (2.3 folds) and small STBEV (2.7 folds) compared to LOPE 
medium/large STBEV and small STBEV (p = 0.0006 (12 hours) p<0.000.1 (24 hours) ; Figure 
10A); whilst at 24 hours, THP-1 challenged with LOPE small STBEV secreted up to 2folds 
more of VEGF than NP small STBEV (p<0.05; Figure 10A). 
Overall, our multiplex data revealed that medium/large and small STBEVs from LOPE 
placenta were less pro-inflammatory than those obtained from NP placentas. These results 





PE, most distinctly EOPE, is thought to originate from poor placentation in the first half of 
pregnancy, leading to ineffective remodelling of the uterine spiral arteries. This causes a high-
pressure pulsatile flow in the intervillous space, which in turn causes excess oxidative and 
hydrostatic stress to the placenta (1). Thus, EOPE has been associated with a vigorous maternal 
systemic inflammatory response to a damaged placenta (44), significant fetal growth 
restriction, and the increasing amounts of STBEV shedding with different phenotype and cargo 
compared to a healthy pregnancy (37,45).  The late-onset disease is subject to several different 
theories of pathophysiology, two prominent ones being trophoblast villus overcrowding 
leading to oxidative stress and maladaptation of the maternal cardiovascular system as putative 
causes.  Despite this, a role for the placenta is still evident since delivery brings about an end 
to PE-associated symptoms in both EOPE as well as LOPE. STBEV (medium/large STBEV 
and small STBEV) have been suggested to play different roles in the pathophysiology, with 
medium/large STBEV playing a more significant role in pro-inflammatory events compared to 
small STBEV (46). We decided to use the THP-1 cell line to avoid patient-related variations 
using PBMCs. By using PMA-differentiated THP-1 cells, we wanted to understand the likely 
true effect of STBEV on both circulating monocytes and tissue macrophages rather than just 
tissue macrophages. Therefore, we hypothesised that the LOPE placenta would release 
STBEVs, which might have a similar immunomodulatory impact to EOPE, i.e. pro-
inflammatory. However, we observed a significantly weakened inflammatory effect of 
STBEVs isolated from LOPE placentae on THP-1 cells. While we could not find a perfect 
gestational age-matched control for the LOPE placentas, we ensured that the average difference 
between the two groups was not more than two weeks. In addition, all samples were collected 
within the last trimester. We used the same EV particle number to control for EV variability 
that can be attributed to gestation age. 
Our study shows that both STBEV types (medium/large STBEV and small STBEV) interact 
with macrophages and modulate their functions.  Flow cytometry revealed co-localisation of 
medium/large STBEV derived from both NP and LOPE placentae to THP-1 macrophages.  
Confocal microscopy confirmed that this co-localisation was secondary to the internalisation 
of the STBEV.  PLAP-based ELISA showing that THP-1 cells internalised placental-derived 
EV further confirmed this. THP-1 cells do not express PLAP, and the detection of PLAP in 
STBEV treated cells after washing suggests internalisation or/and membrane fusion of the 
STBEVs and THP-1 cells. This is in line with previous work showing mature PBMCs from NP 
donors phagocytosed SW71 trophoblast cell-derived EV (47) as well as medium/small STBEV 
isolated from dual perfusion (30).  When assessing PLAP levels within the THP-1 cells, we 
were unable to see any significant difference in the uptake of NP and PE STBEV. We were 
able to determine enhanced uptake of medium/large STBEV compared to small STBEV in both 
NP and LOPE.   
Analysis of gene expression via RT-qPCR and cytokine/chemokine secretion via multiplex 
array revealed that exposure of PE STBEV to THP-1 macrophages had significantly less 
inflammatory impact compared to NP STBEV. NP STBEV, especially NP medium/large 
STBEV, induced a pro-inflammatory response by THP-1 macrophages.  Previous studies have 
shown that NP placental microvesicles induced significant levels of TNF-α, MIP-1α, IL-1α, 
IL-1β, IL-6 and IL-8  (30,48) and an increased release of IFN-γ, IL-12, IL-18 and TNF-α by 
PBMCs (33).  Similarly, NP medium/large STBEV derived from in vitro explant cultures from 
human placentae have been shown to enhance secretion of IL-1β, IL-6 and IL-8 by PBMCs 
(31).  Correspondingly, exosomes derived from SW71 trophoblast cells have been shown to 
increase monocyte migration and production of IL-1β, IL-6, G-CSF, GM-CSF and TNF-α (47).  
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Collectively, our NP results are consistent with these studies. The pro-inflammatory 
microenvironment and cytokines such as IL-1, IL-6, leukocyte inhibitory factor (LIF)(49), 
IFN-γ(50), IL-8, TNF-α, MCP-1 are necessary for implantation, spiral artery remodelling, and 
during parturition(51). TNF-α facilitates local cytokine balance at the decidua that facilitates 
maternal-feto-placenta unit interaction(52). MCP-1 attracts macrophages into the endometrium 
to maintain M1/M2 balance and prevent rejection of the foetus earlier in pregnancy(53). TGF-
β controls apoptosis and proliferation of endometrial cells and facilitates endometrial 
receptivity during the peri-implantation period(54). IL-1 β, IL-6, TNF-α and IL-8 expression 
is increased in the myometrium and cervix during parturition(55). IL-1 β plays a role in 
initiating parturition by causing calcium influx into smooth muscle cells(56). IL-10 is increased 
in the placenta of normal pregnancy compared to high-risk pregnancies(57) and regulates 
trophoblastic invasion(58), regressing the pro-inflammatory microenvironment(59) that 
occurred in early pregnancy and promoting angiogenesis due to the production of trophoblastic 
VEGF-C and aquaporin 1. Shortly before parturition, its level decline in other to facilitate the 
onset of labour(60). IL-6 activates and differentiates B and T cells (61) and stimulates M2 
macrophage polarisation, promoting invasion and migration of macrophages(61). The 
individual functions of a number of these cytokines and their roles in implantation, pregnancy 
and parturition still require more profound research. Collectively, our NP results are consistent 
with these studies.  Most surprising, however, was the significantly lower pro-inflammatory 
effect seen with LOPE STBEV. We made an effort, in three different ways,  to confirm that 
the STBEV in both conditions were being internalised by the THP-1 cells; this ruled out the 
possibility that LOPE vesicles were not causing a pro-inflammatory effect because they were 
not being internalised.  
Small STBEVs have not been extensively studied, but some groups have suggested that NP 
placenta explants derived exosomes have immunosuppressive roles (62,63). Our study shows 
that small NP STBEVs are capable of causing an inflammatory phenotype while LOPE small 
STBEVs echo the results that we obtained from medium/large STBEV in that they did not 
display the expected pro-inflammatory response. Thus, in contrast to EOPE, any inflammation 
in LOPE is unlikely to be because of crosstalks between macrophages and STBEVs. 
Alternative inflammatory mechanisms may involve interactions with other immune cells in the 
decidua, such as the uterine Natural Killer cells or lymphocytes or non-immune cells such as 
the decidua stroma cells. Similarly, systemic inflammation may be propagated through 
STBEVs interaction with other cells in the circulation such as neutrophils or B-cells or by 
directly activating the complement system that can stimulate the inflammatory response in 
LOPE (26).  Tannetta et al. provided evidence that STBEV isolated from NP can cause platelet 
activation, which is augmented by PE STBEV (64).  Increased platelet reactivity due to 
exposure to STBEV from PE might correlate with the increased thrombotic risk associated with 
PE, possibly leading to the inflammatory response (64). STBEV have also been shown to have 
anti-angiogenic and hypertensive effects preventing endothelial cell monolayer growth in vitro 
as well as inhibiting relaxation of pre-constricted blood vessels in vivo (65–67).   
Our study also differs from the observations of Abumaree et al who noticed that placenta debris 
have an immunosuppressive effect on PBMCs. This might be because 1) pooled PBMCs were 
used with their inherence patient variability; 2) placenta debris was isolated from explants and 
not perfused placentas, and 3) the placenta debris obtained did not discriminate into the 
subtypes of EVs and may contain other materials aside EVs. Plasma EV derived from PE 
patients in comparison to those from NP has been shown to affect monocyte functions, such as 
altered phagocytosis-associated molecular pattern, decreased chemotactic and migratory 
activity, and increased adhesiveness (68).  Unfortunately, this previous study did not focus on 
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STBEV.  Hence, we cannot conclude that the immunosuppressive effect observed to have been 
exerted by the placenta debris is directly due to placenta-derived EV.  Alternatively, STBEV 
derived from LOPE might have an impact. Although these studies have not separated 
microvesicles and exosomes and differentiated EOPE to LOPE, it is necessary to consider their 
findings when interpreting our results. 
Studies have shown key differences between EOPE and LOPE, supporting the idea that these 
are separated disease entities. Women with PE show an imbalance between a pro-inflammatory 
and anti-inflammatory profile in CD4+ T-cell subsets with polarisation to TH17 profiles, 
predominantly in EOPE (69).  Notably, this study reported endogenous plasma levels of IL-6, 
IL-7 and TNF-α to be significantly higher in the EOPE group than in the LOPE and control 
groups (69). Another study found substantially higher concentrations of Hsp70, TNF-α, IL-1β, 
IL-12, and sTNFRI in patients with EOPE compared to LOPE, as well as significantly lower 
IL-10 levels in the EOPE group (70).  EOPE was, therefore, associated with higher maternal 
and fetal impairment, highlighting differences in the pathophysiology between EOPE and 
LOPE (70).   
No studies have been performed examining the effects of STBEV from LOPE placenta on 
immune function. Our data suggest that the differences seen in immune function in EOPE and 
LOPE may well in part be mediated by the differences in the effects of STBEV from these 
disease states. In addition, the apparent pro-inflammatory phenotype seen in LOPE might not 
be caused by a direct effect of STBEVs on macrophages but rather an effect on another yet to 
be determined immune or non-immune cell type(s) (e.g. uterine NK cells,  T cells, neutrophils, 
platelets) or through direct activation of the complement system by the STBEVs.  
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Table 1.  Clinical data of human subjects.  Data presented as Mean ± SEM, significant 
difference shown as p<0.01 (**) or not significant (ns).   
 







Age (years) 37.3 ± 0.7  32.7 ± 4.7 ns 
Gestation Age (weeks + days) 38+1 ± 6.5  36+0 ± 5 * 
Mean no. of pregnancies 2.3 ± 0.3 0.7 ± 0.3 ** 
Body Mass Index (kg/m
2
) 27.3 ± 2.4 37.1 ± 6.7 ns 
Max. Proteinuria qPCR (mg/mmol) 16.1 ± 8.6 256.7 ± 168.7 ** 
Max. Systolic pressure (mm Hg) 137.3 ± 1.8 181 ± 15.9 ** 
Max. Diastolic pressure (mm Hg) 81.7 ± 8.7 108.7 ± 6.3 ** 
New-born weight (g) 4008 ± 137.2 2418 ± 66 ** 
Smoking History 3/6 2/6 ns 
 
 





Forward Primer Reverse Primer Source 
18S 5’-ATGGCCGTTCTTAGTTGGTG-3’ 5’-CGCTGAGCCAGTCAGTGTAG-3’ Sigma-Aldrich 
TNF- α 5’-AGCCCATGTTGTAGCAAACC-3’ 5’-TGAGGTACAGGCCCTCTGAT-3’ Sigma-Aldrich 
TGF- β 5’-GTACCTGAACCCGTGTTGCT-3’ 5’-GTATCGCCAGGAATTGTTGC-3’ Sigma-Aldrich 
IL-10 5’-TTACCTGGAGGAGGTGATGC-3’ 5’-GGCCTTGCTCTTGTTTTCAC-3’ Sigma-Aldrich 
IL-12 5’-AACTTGCAGCTGAAGCCATT-3’ 5’-GACCTGAACGCAGAATGTCA-3’ Sigma-Aldrich 
IL-8 5’-CTGTGTGAAGGTGCAGTTTTG-3’ 5’-GTGTTGGCGCAGTGTGGTC-3’ Sigma-Aldrich 









Figure 1A Representative Western blot image of placenta lysate (PL), medium/large STBEVs 
(n=3) and small STBEVs (n=3) showing expression of extracellular vesicle markers (ALIX, 
TSG101, CD63 and CD81), syncytiotrophoblast origin marker (PLAP) and negative 
expression of cytochrome C. Figure 1B, C, D and E are representative flow cytometry analysis 
graphs of medium/large STBEVs derived from the placentae. B shows the per cent of vesicles 
in the medium/large STBEVs enriched sample fraction (based on the per cent of bio-maleimide 
positive events), C shows the per cent of PLAP positive extracellular vesicles, D shows the per 
cent of MHC I/II negative extracellular vesicles. In contrast, E shows the per cent of platelet 
and endothelial cells derived vesicles in our samples.  
Figure 2. Figures 2A and D are nanoparticle tracking analysis (NTA) graphs of medium/large 
and small STBEVs, respectively, while B (wide angle) and C (close-up) are transmission 
electron microscopy images of medium/large STBEVs. Figures 2 E (wide angle) and F (close 
up) are transmission electron microscopy images of small STBEVs 
Figure 3.  Flow cytometry analysis of the uptake of medium/large STBEV derived from NP 
and PE placentae by differentiated THP-1 cells (n=3).  Bio-Maleimide pre-stained 
medium/large STBEV characterisation (A).  Representative SSC vs FSC graph with chosen 
EV population to be less than 1 micron in size (characterised as microvesicles), followed by 
SSC vs Bio-Maleimide-FITC channel graph showing the chosen 1% cut-off gate using non-
stained medium/large STBEV and Bio-Maleimide stained medium/large STBEV.  Treatment 
of Bio-Maleimide stained medium/large STBEV to HLA-ABC stained THP-1 macrophages 
(B).  Representative Bio-Maleimide-FITC vs HLA-ABC-PeCy7 graph at 2 and 6 h treatment 
showing untreated THP-1, then treated ThP-1 with medium/large STBEV derived from NP and 
PE placentae.  Bar-graph demonstrating merged results from THP-1 macrophages untreated 
and treated with NP and PE medium/large STBEV (C) plotted as HLA-ABC+ Bio-Maleimide+ 
against incubation period.  Data presented as Mean ± SEM, significant difference shown as 
p<0.001 (***) and p<0.0001 (****). 
Figure 4. The internalisation of medium/large STBEVs from NP and PE placentae into THP-
1 cells by confocal microscopy (technical replicate =3). Medium/large STBEVs derived from 
NP and PE patients incubated for 2 and 6 hours incubation with differentiated THP-1 cells.  
Channels panel show cells’ nuclei labelled with Hoechst dye (blue), cells’ membrane labelled 
with WGA Alexa 488 (green), STBEVs labelled with PKH26 dye (red) and merged channels.  
ThP-1 only incubated with no STBEVs are used as the control. This control also served as the 
control for the experiment to detect internalisation of small STBEVs from NP and PE placentae 
into THP-1 cells (Figure 5).  Scale bars, 10 μm.   
Figure 5. The internalisation of small STBEVs from NP and PE placentae into THP-1 cells by 
confocal microscopy (technical replicate =3). Small STBEVs derived from NP and PE patients 
incubated for 2 and 6 hour incubation with differentiated THP-1 cells.  Channels panel show 
cells’ nuclei labelled with Hoechst dye (blue), cells’ membrane labelled with WGA Alexa 488 
(green), STBEVs labelled with PKH26 dye (red) and merged channels.  THP-1 only incubated 
with no STBEVs (from Figure 4) was used as the control. Scale bars, 10 μm.    
Figure 6.  ELISA using STB specific marker, PLAP, on THP-1 macrophages treated with 
STBEVs derived from NP and PE placentae at 2 and 6 hour incubation. THP-1 cells do not 
innately express PLAP while STBEVs do. The presence of detectable PLAP in treated THP-1 
cells indicate internalisation or/and fusion. Quantification analysis of NP and PE medium/large 
STBEVs and small STBEVs expressing PLAP marker internalised by THP-1 macrophages.  
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Data presented as Mean ± SEM, significant difference shown as p<0.001 (***) and p<0.0001 
(****).   
Figure 7.  RT-qPCR analysis of the medium/large STBEV induced expression of cytokines by 
differentiated ThP-1 cells.  Cells were incubated with medium/large STBEVs from NP and PE 
placentae at 2- and 6-hour time-points.  In control experiments, cells were incubated with 
filtered PBS at the same time-points.  mRNA expression was measured using real-time RT-
qPCR for medium/large STBEVs; TNF-α (A), TGF-β (B), IL-10 (C), IL-12 (D), IL-8 (E) and 
IL-6 (F). Data were normalised to 18S rRNA expression that was used as an internal reference 
gene.  Values calculated as mean ± SEM of value from cells treated with 1 X 109 of 
medium/large STBEVs. To determine significant difference in expression, one-way ANOVA 
was performed on data: * p≤ 0.05, ** p≤ 0.01, *** p≤ 0.001 and **** p< 0.0001.   
Figure 8.  RT-qPCR analysis of the small STBEV induced expression of cytokines by 
differentiated THP-1 cells.  Cells were incubated with small STBEVs from NP and PE 
placentae at 2- and 6-hour time-points.  In control experiments, cells were incubated with 
filtered PBS at the same time-points.  mRNA expression was measured using real-time RT-
qPCR for small STBEVs; TNF-α (A), TGF-β (B), IL-10 (C), IL-12 (D), IL-8 (E) and IL-6 (F). 
Data were normalised to 18S rRNA expression that was used as an internal reference gene.  
Values calculated as mean ± SEM of value from cells treated with 1 X 109 of STBEV. To 
determine significant difference in expression, one-way ANOVA was performed on data: * p≤ 
0.05, ** p≤ 0.01, *** p≤ 0.001 and **** p< 0.0001.   
Figure 9.  Multiplex array analysis of the supernatants of differentiated THP-1 cells treated 
with STBEVs from NP and PE placentae.  Concentrations of TNF-α (A), IL-10 (B), IL-8 (C), 
IL-6 (D), MIP-α (E), MCP-1 (F)released by THP-1 cells at 12 and 24 h incubation with 
STBEVs.  Values calculated as Mean ± SEM of value from cells treated with 1 X 109 of 
STBEVs. Bars without error bars represent data whose SEM are close to zero and could not be 
adequately plotted by prism. To determine significant difference in production, a one-way 
ANOVA was performed on data: * p≤ 0.05, ** p≤ 0.01, *** p≤ 0.001 and **** p≤ 0.0001. 
Figure 10.  Multiplex array analysis of the supernatants of differentiated THP-1 cells treated 
with STBEVs from NP and PE placentae.  Concentrations of VEGF(A), IL-1β (B), GM-CSF 
(C), IL-12p40 (D) and IP-10 (E) released by THP-1 cells at 12 and 24 h incubation with 
STBEVs.  Values calculated as Mean ± SEM of value from cells treated with 1 X 109 of 
STBEVs. Bars without error bars represent data whose SEM are close to zero and could not be 
adequately plotted by prism. To determine significant difference in production, a one-way 
ANOVA was performed on data: * p≤ 0.05, ** p≤ 0.01, *** p≤ 0.001 and **** p≤ 0.0001. 
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